Going forward, special attention should be paid to the exploration of potential unwanted effects, particularly those affecting cardiovascular health with heart rate being one of the easiest variables to monitor
"With no new FDA-approved medications for AUD since 2006, identifying new therapeutic options is especially critical
Following the completion of these trials, the developer is expected to submit a New Drug Application (NDA) to the FDA in early 2027
ACHIEVE-3 is a 52-week randomized, open-label trial including 1698 participants across the US, Argentina, China, Japan, Mexico, and Puerto Rico
An open-label, single-arm trial of the safety and efficacy of a novel preparation of glutathione as a skin-lightening agent in Filipino women, Pubmed